21 – 30 of 191
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
- Contribution to journal › Scientific review
-
Mark
Koagulationsfaktor XIII – inte bara ett kongenitalt blödningsproblem
- Contribution to journal › Scientific review
-
Mark
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
- Contribution to journal › Article
-
Mark
Considerations for shared decision management in previously untreated patients with hemophilia A or B
- Contribution to journal › Scientific review
-
Mark
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice
- Contribution to journal › Article
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
- Contribution to journal › Article
-
Mark
High use of pain, depression, and anxiety drugs in hemophilia : more than 3000 people with hemophilia in an 11-year Nordic registry study
- Contribution to journal › Article
- 2022
-
Mark
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
- Contribution to journal › Article
-
Mark
Autologous cell therapy - A new concept to eradicate inhibitors in haemophilia
- Contribution to journal › Letter
-
Mark
Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children : A critical review from the physician's perspective
- Contribution to journal › Scientific review
